Discontinuation report DEPO-PROVERA
Report ID | 178953 |
Drug Identification Number | 00585092 |
Brand name | DEPO-PROVERA |
Common or Proper name | MEDROXYPROGESTERONE ACETATE SUSPENSION |
Company Name | PFIZER CANADA ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | MEDROXYPROGESTERONE ACETATE |
Strength(s) | 150MG |
Dosage form(s) | SUSPENSION |
Route of administration | INTRAMUSCULAR INTRAMUSCULAR |
Packaging size | 1 x 1mL |
ATC code | G03AC |
ATC description | HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | |
Actual discontinuation date | 2022-08-05 |
Remaining supply date | 2022-08-05 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | As indicated on posting 131486, product in status CANCELLED POST MARKET. No more supply in Vial format for Depo-Provera. Other presentation available, pre-filled syringes (DIN 02523493). |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v2 | 2022-12-20 | French | Compare |
v1 | 2022-12-20 | English | Compare |
Showing 1 to 2 of 2